deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT03272477

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients (TP-II)

A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertuzumab in Combination With Standard (Neo)Adjuvant Treatment in Patients With Operable HER2+/HR+ Breast Cancer.

Sponsor: Cankado GmbH

Conditions Breast Neoplasms
Interventions Anastrozole Biopsy Cyclophosphamide Epirubicin Exemestane Goserelin Herceptin Letrozole Leuporelin acetate Leuprorelin acetate Paclitaxel Perjeta Injectable Product Surgery Tamoxifen
Updated 14 times since 2017 Last updated: Apr 16, 2024 Started: Oct 5, 2017 Primary completion: Jul 14, 2020 Completion: Mar 4, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03272477, this PHASE2 trial focuses on Breast Neoplasms and remains completed. Sponsored by Cankado GmbH, it has been updated 14 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~May 2019 · 7 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~May 2020 · 11 months · monthly snapshot~May 2020 – ~Sep 2020 · 4 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Oct 2021 · 9 months · monthly snapshot~Oct 2021 – ~Nov 2022 · 13 months · monthly snapshot~Nov 2022 – ~Dec 2023 · 13 months · monthly snapshot~Dec 2023 – ~May 2024 · 5 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 24 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. May 2024 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Dec 2023 — May 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Nov 2022 — Dec 2023 [monthly]

    Active Not Recruiting PHASE2

▶ Show 9 earlier versions

  1. Oct 2021 — Nov 2022 [monthly]

    Active Not Recruiting PHASE2

  2. Jan 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  4. May 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE2

  5. Jun 2019 — May 2020 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  6. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  7. Oct 2018 — May 2019 [monthly]

    Recruiting PHASE2

  8. Jun 2018 — Oct 2018 [monthly]

    Recruiting PHASE2

  9. Oct 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cankado GmbH
  • Palleos Healthcare GmbH
  • Roche Pharma AG
  • WSG WOMEN´S HEALTHCARE STUDY GROUP
Data source: Palleos Healthcare GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations